west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "凝血功能" 22 results
  • Evaluation of Coagulation in Orthotopic Liver Transplantation with Thrombelastography

    ObjectiveTo evaluate the changes in thrombelastography(TEG) during orthotopic liver transplantation (OLT) in Chinese. MethodsTwentyfive patients with cirrhosis of liver undergoing OLT were studied. They were composed of two groups: cirrhosis group (n=15) and liver neoplasm group (n=10). Anesthesia was induced with propofol 1.5-2 mg/kg,fentanyl 3-5 μg/kg and vecuronium 0.1 mg/kg and maintained with isoflurane or enflurane inhalation.The operation was divided into three phases: ① before operation and preanhepatic phase (120 min after operation was started), ② 30 min after liver was removed,③ 5 min before reperfusion and 5 min,15 min,30 min,60 min and 120 min after reperfusion.In 8 patients among the 25 patients heparinasecelite TEG was measured 5 min after reperfusion in addition to celite TEG.If there was significant differences in traces between the two TEG measurements,an intravenous bolus of 50-75 mg protamine was given and the heparinasecelite TEG was repeated.The measured variables included the r (reaction) time,representing the rate of initial fibrin formation K (coagulation) time, alpha angles (α) reflecting fibrinplatelet interaction, MA (maximal amplitude) indicating qualitative platelet function and percent fibrinolysis at 60 min. ResultsIn cirrhosis group changes in TEG occurred after liver was removed and in earlier period after reperfusion, while in liver neoplasm group changes in TEG were found in earlier period after reperfusion as compared with preoperative value.At 5 min after reperfusion there were significant differences in TEG (r,K,α and MA) values between celite and heparincelite TEG (P<0.01). ConclusionDuring OLT coagulation disorder occurs mainly at anhepatic and early reperfusion phase.

    Release date:2016-08-28 04:49 Export PDF Favorites Scan
  • Coagulation Function Test in Esophageal Carcinoma and Its Clinical Significance

    Objective To show the changes of coagulation function in patients with esophageal carcinoma, and to explore the clinical significance of the changes. Methods We retrospectively analyzed the clinical data of 202 patients(as a trial group, 114 males, 88 females, aged from 36 to 69 years, median age at 49 years) with esophageal carcinoma confirmed by pathological examination in Gansu Provincial Hospital from January 2010 through May 2014. The prothrombin time (PT), prothrombin time activity (PTA), international activated partial thromboplastin time (APTT), fibrinogen (Fib), D-Dimer, and platelet count, pathological type, TNM stage, gender were recorded. Eighty patients (38 males, 42 females, with aged of 39 to 71 years, median age of 51 years) without cancer were selected as a control group. Results Compared with the control group, coagulation parameters including PT, APTT, PLT, Fib, TT, D-Dimer were statistically higher in the trial group (P<0.05). Higher Fib level was found in the squamous cell esophageal carcinoma patients than adenocarcinoma cell esophageal carcinoma patients (P<0.05). Fib increased significantly (P<0.05) and APTT shorten (P<0.05) in the patients at stage Ⅲ and stage Ⅳ compared with those of patients at stage Ⅰ and stage Ⅱ. Fib and D-Dimer levels increased (P<0.05) in N1-3 patients compared with those of N0 patients. There was no statistical difference in gender or age (P>0.05) between the two groups. Conclusion Most of the patients with esophageal carcinoma have abnormal changes of coagulation and fibrinolysis system. Patients with squamous subtype and/or lymph node metastasis at advanced stages of esophageal carcinoma are prone to thrombophilia. So monitoring the coagulation parameters of cancer patients can be used as an effective measure to prevent blood clot.

    Release date: Export PDF Favorites Scan
  • Changes on Perioperative Coagulation Function of Orthotopic Liver Transplantation inPatients with Advancing Chronic Hepatopathy and Fulminant Hepatitis

    目的 比较进展性慢性肝病及重症肝炎患者原位肝移植(OLT)围手术期凝血功能的变化。方法 回顾性分析我中心2004年1月至2005年12月期间行OLT治疗进展性慢性肝病及重症肝炎患者各37例的围手术期血小板(PLT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)及纤维蛋白原(FIB)的变化。结果 2组患者除术前PT、APTT,术后第5 d PLT、FIB和术后第7 d FIB的差异有统计学意义外(plt;0.05),其余时段2组患者的PLT、PT、APTT及FIB 间差异均无统计学意义(Pgt;0.05), 提示重症肝炎患者凝血功能损害更为严重; OLT术后,2组患者的凝血功能均逐渐恢复正常, 但并非完全同步。结论 进展性慢性肝病与重症肝炎患者OLT围手术期凝血功能变化显著,应注意监测及处理,但术后2组间各指标间比较差异并不明显。

    Release date:2016-09-08 11:07 Export PDF Favorites Scan
  • Paroxysmal Acquired Coagulopathy Caused by Anticoagulant Rodenticides: A Report of Three Cases and the Literature Review

    目的 分析反复发作的抗凝血类灭鼠药所致获得性凝血功能障碍的临床特点,探讨其诊治方案。方法 对2009年3月-2010年12月收治的3例抗凝血类灭鼠药所致获得性凝血功能障碍患者的临床表现、实验室检查和治疗转归进行分析,并复习相关文献。 结果 3例患者均以同时出现多部位出血为首发表现,经应用维生素K1、凝血酶原复合物、新鲜冰冻血浆、冷沉淀等治疗,患者病情好转,实验室指标恢复正常。停药(2、5周,3个月)后再次出现多部位出血,再给予维生素K1等治疗,病情可缓解。 结论 维生素K1可作为首选的治疗药物,且对反复发作的患者同样有效。为避免再发性出血,应维持治疗至少3个月。

    Release date: Export PDF Favorites Scan
  • A Study on the Correlation between Traumatic Coagulopathy and Traumatic Brain Injury

    目的:探讨脑损伤患者凝血功能水平与颅脑损伤伤情转归的相关性。方法:收集70例颅脑损伤患者的临床资料,伤者抽取静脉血2 mL,进行凝血功能检测,分析结果与临床资料等分别采用SPSS 11.5软件进行χ2检验和logistic回归分析。结果:在13例凝血功能异常患者中有5例(38%)伤情加重(较入院时脑内血肿体积增大,迟发性血肿等),明显高于凝血功能正常而伤情加重者(12%,Plt;0.05);单因素和多因素logistic回归分析提示凝血功能异常时脑损伤伤情加重的危险因素。结论:脑创伤后凝血功能异常时颅脑损伤患者伤情加重的危险因素。

    Release date:2016-09-08 09:56 Export PDF Favorites Scan
  • Effects of component blood transfusion combined with heparin therapy on coagulation function and clinical outcomes in pregnant women with acute disseminated intravascular coagulation

    Objective To investigate the effects of component blood transfusion combined with heparin therapy on coagulation function and clinical outcomes in pregnant women with acute disseminated intravascular coagulation (DIC). Methods A retrospective analysis was conducted on the clinical data of 65 pregnant women with acute DIC who were treated in Obstetrics Department of Luzhou People’ s Hospital between March 2020 and March 2022. Pregnant women treated with component blood transfusion were included in the control group, while those treated with component blood transfusion combined with heparin were included in the observation group. Before and after treatment, the DIC scoring system was used for score evaluation. Coagulation function indicators and routine blood indicators were compared between the two groups of pregnant women. Adverse clinical outcomes and adverse reactions were observed in both groups of pregnant women. Results The study enrolled 65 pregnant women, comprising 30 in the observation group and 35 in the control group. Before treatment, there was no statistical difference in DIC score, coagulation function indicators, or routine blood indicators between the two groups (P>0.05). After treatment, the DIC score, prothrombin time, activated partial thromboplastin time, thrombin time, and D-dimer significantly decreased in both groups (P<0.05), and the above indicators in the observation group [3.39±0.48, (13.28±2.28) s, (24.68±2.06) s, (14.27±1.82) s, and (2.23±0.88) mg/L, respectively] were lower than those in the control group [4.11±1.56, (15.02±2.45) s, (26.79±3.18) s, (15.61±1.91) s, and (2.87±0.74) mg/L, respectively] (P<0.05). The levels of fibrinogen, platelet count, hemoglobin, and hematocrit significantly increased in both groups (P<0.05), and the levels in the observation group [(4.29±1.05) g/L, (175.36±20.46)×109/L, (84.09±7.27) g/L, and (25.49±3.13)%, respectively] were higher than those in the control group [(3.44±1.27) g/L, (145.77±21.12)×109/L, (76.58±7.13) g/L, and (23.03±3.05)%, respectively] (P<0.05). The observation group had a lower incidence rate of adverse clinical outcomes compared to the control group (33.3% vs. 74.3%, P<0.05). The incidence rates of adverse reactions were not statistically different between the two groups (P>0.05). Conclusions Component blood transfusion combined with heparin therapy for pregnant women with acute DIC can effectively improve their coagulation function, reduce the risk of bleeding, and further improve adverse clinical outcomes such as postpartum hemorrhage and hysterectomy. Additionally, this treatment approach demonstrates a high safety profile.

    Release date:2025-08-26 09:30 Export PDF Favorites Scan
  • The blood clotting dysfunction and therapeutic efect of low molecular hepa~n in a mouse model of invasive pulmonary aspergillosi

    Objective To investigate the blood clotting dysfunction of invasive pulmonary aspergillosis(IPA)and the therapeutic effect of low molecular hepafin in a mouse model.Methods The neutropenic IPA mouse model was constructed by being given cyclophosphamide to depress immunologic function,and then intranasally challenged with Aspergillus fumigatus conidia.(1)Blood clotting function were assessed by bleeding time,clotting time,platelet count and antithrombase-III(AT-III)activity.Seventy-two mice were randomly assigned into 4 groups.Group A received only normal saline.group B received normal saline to substitute the cycloph0sphamide,and the rest equal to group D.Group C received normal saline to substitute the AspergiUus fumigatus conidia suspension,and the rest equal to group D.Group D(model group)received cyclophosphamide(intraperitoneally,150 mg/kg,d4,d1)and Aspergillus fumigatus conidia suspension(intranasally,40 μL/mouse,1.5×10∧5/mL,d0).Six mice were randomly sacrificed in each group for analysis of blood clotting function per 24 h after inoculation for 3 times.(2)Therapeutic effect of low molecular heparin was determined by survival time of IPA mice.One hundred and eighteen mice were randomly assigned into 4 groups after challenged with 6×10 conidia/mouse and received one of the following regimens daily from dl to d7 after challenge,vehicle(group E,n=29),low molecular heparin(group F,n=30,subcutaneous injection,1000 IU/kg,qd×7 d),amphotericin B(group G,n=29,intraperitoneal,1 m kg,qd×7 d),low molecular heparin plus amphotericin B(group H,n=30).Mice survivals were recorded once daily to d21 after innoculation.Results (1)AT-III activity of group D decreased significantly 24 h after innoculation.Bleeding time and clotting time decreased significantly and AT—III activity decreased sequentially 48 h after innoculation.The platelet decreased significantly 72 h after innoculation,and bleeding time shoaened further.Clotting time was longer than that 0f 48 h.but still shorter than norm al and AT-III activity decreased sequentially.There were significant differences when comparing group D with group A,B and C(all Plt;0.01).And there was no significant difference between group A,B and C(all Pgt;0.05).(2)Survival analysis indicated that the therapeutic effect of low molecular hepafin plus amphotericin B was better than that of amphotericin B or low molecular heparin alone.No therapeutic effect was found in group F(group E vs group F,Pgt;0.05,both group E and group F compared with group H,P lt;0.01.Group H vs group G,P lt;0.05.Both group E and group F compared with group G,P lt;0.05).Conclusions The results suggest that there is blood clotting dysfunction in IPA mice and AT—III activity may be an early index to monitor the disfunction.Compared with the therapeutic effect of amphoterinein B alone,low molecular hepafin plus amphoterincin B can prolong survival of neutropenic IPA mice

    Release date:2016-09-14 11:57 Export PDF Favorites Scan
  • Study on Correlation Between The Lipopolysaccharide, Interleukin-6,Platelet Activating Factor,and Coagulation Dysfunction after Severe Thoracic and Abdominal Trauma

    目的 探讨脂多糖(LPS)、白细胞介素-6(IL-6)和血小板活化因子(PAF)与重症胸腹创伤后凝血功能紊乱发生的相关性及可能的致病机理。方法 收集2009年1月至2011年12月期间在中国人民解放军第二五三医院急诊科就诊、创伤指数≥17分且除外合并颅脑损伤及在急诊科内死亡的胸腹创伤患者62例,在予以抢救、治疗的同时抽血检查血小板计数(PLT)、血浆D-二聚体(D-D)、部分活化凝血酶原时间(APTT)、凝血酶原时间(PT)、LPS、IL-6和PAF,并对其结果进行相关性分析。结果 本组患者就诊时检测的PLT为(157.73±78.11)×109/L, D-D为(1 023.88±208.72) U/L,APTT为(46.95±17.85) s,PT为(19.44±6.95) s,TT为(58.27±12.44)s,除PLT降低外,其余4项指标均升高或延长; LPS为(322.85±104.54) U/L,IL-6为(285.51±81.46) ng/mL,PAF为 (14 714.70±4 427.95) ng/L, 三者均升高; PLT与LPS、IL-6和PAF之间呈负相关关系(P<0.001),而D-D、APTT、PT和TT与LPS、IL-6和PAF之间均呈正相关关系(P<0.001)。结论 LPS、IL-6及PAF可能参与了重症胸腹创伤后凝血功能障碍的发生;重症胸腹损伤后出现的微循环障碍及内毒素血症是凝血功能障碍发生的重要机理。针对LPS、IL-6和PAF进行早期干预,有可能改善重症胸腹创伤患者的凝血功能障碍。

    Release date:2016-09-08 10:35 Export PDF Favorites Scan
  • Correlations between Lipopolysaccharide, Phospholipase A2 and Platelet-activating Factor with Coagulopathy after Severe Chest and Abdominal Injuries and Their Mechanisms

    ObjectiveTo investigate the correlations between lipopolysaccharide(LPS), phospholipase A2 (PLA2) and platelet-activating factor (PAF) with coagulopathy after severe chest and abdominal injuries and their mechanisms. MethodsClinical data of 82 patients with severe chest and abdominal injuries whose trauma index (TI) was greater than or equal to 17 points in No. 253 Hospital of People's Liberation Army from January 2009 to June 2012 were retrospectively analyzed (severe chest and abdominal injury group). Those patients who had concomitant traumatic brain injuries or died in the Emergency Department were excluded from this study. There were 58 male and 24 female patients with their age of 16-76 (43.59±16.33)years. There were 17 patients with open injuries and 65 patients with closed injuries. There were 23 patients with fall injuries, 47 patients with traffic injuries, 8 patients with blunt force injuries, and 4 patients with penetrating injuries. Forty-two healthy volunteers who received routine medical examinations in the outpatient department of our hospital were chosen as the control group, including 27 males and 15 females with their age of 24-47 (37.32±10.45) years. Blood platelet (PLT) count, D-dimer (D-D), activated partial thromboplastin time (APTT), LPS, PLA2 and PAF were compared between the 2 groups, and linear correlation analysis was performed. ResultsPLT of the severe chest and abdominal injury group patients were significantly lower than that of the control group[(83.44±38.52)×109/L vs. (191.52±23.31)×109/L]. D-D[(1 823.89±608.02) U/L vs. (105.78±44.53) U/L], APTT [(68.24±24.12) s vs. (22.47±9.41) s], LPS[(438.66±106.02) U/L vs. (87.38±46.51) U/L], PLA2 [(41.35±14.26) ng/ml vs. (7.47±5.27)ng/ml] and PAF[(15 765.31±4 431.65) ng/L vs. (3 823.45±529.72) ng/L] of the severe chest and abdominal injury group patients were significantly higher than those of the control group(P < 0.001). PLT was significantly negatively correlated with LPS, PLA2 and PAF with all the respective correlation coefficient(r)less than-0.933 5. D-D and APTT were significantly positively correlated with LPS, PLA2 and PAF with all the respective r larger than 0.921 6. ConclusionLPS, PLA2 and PAF participate in the pathogenesis of coagulopathy in patients with severe chest and abdominal injuries. Early intervention against LPS, PLA2 and PAF may improve coagulopathy and survival rate of patients with severe chest and abdominal injuries.

    Release date: Export PDF Favorites Scan
  • 抑肽酶对乙型病毒性肝炎患者体外循环术后凝血功能的影响

    目的探讨抑肽酶对乙型病毒性肝炎(HB)患者体外循环(ECC)心脏手术凝血功能的影响. 方法 52例心脏病患者中,合并HB 33例,未合并HB 19例.33例合并HB患者随机分为两组,A组:17例,ECC中应用抑肽酶;B组:16例,ECC中不用抑肽酶;对照组:19例,为未合并HB患者,ECC中不用抑肽酶.动态监测所有患者的凝血因子Ⅺ促凝活性(FXI:C)、抗凝血酶Ⅲ活性(AT-Ⅲ:A)和D-二聚体的水平变化. 结果 A组术后出血量和输血量明显少于B组(P<0.01);术前3组患者FXI:C,AT-Ⅲ:A和D-二聚体组间比较差别均无显著性意义(P>0.05);术后6小时、24小时,A组FXI:C明显高于B组(P<0.05);3组间AT-Ⅲ:A差别无显著性意义(P>0.05);ECC 20分钟至术后24小时,A组D-二聚体明显低于B组(P<0.01). 结论 HB患者ECC后存在较严重的凝血功能障碍;抑肽酶通过抑制继发性纤溶功能亢进,减少凝血因子的消耗,从而减少HB患者的出血量和输血量.

    Release date:2016-08-30 06:32 Export PDF Favorites Scan
3 pages Previous 1 2 3 Next

Format

Content